Teva reports ecopipam cuts pediatric Tourette tic relapse risk and shows rapid, sustained improvement
Teva Pharmaceuticals presented new data on ecopipam, an investigational selective D1 dopamine receptor antagonist for pediatric Tourette syndrome. A Phase 3 trial of 216 participants (167 pediatric) showed a 50% reduction in tic relapse risk versus placebo (hazard ratio 0.5, p=0.008). In pooled analyses, 69.8% of patients achieved at least a 25% reduction in tic severity within eight weeks, and benefits were maintained through 18 months with a 45.6% mean reduction. The FDA has granted Priority Review and Orphan Drug designation for the pediatric indication.
Why it matters
The company says approval would make ecopipam the first new therapy for pediatric Tourette syndrome in over a decade, potentially expanding Teva's revenue base. FDA Priority Review could accelerate the approval timeline, which may positively affect the stock price.
Key facts
- 1The Phase 3 trial enrolled 216 participants, including 167 pediatric patients. stocktitan.net
- 2Continued ecopipam reduced pediatric tic relapse risk by 50% versus placebo (hazard ratio 0.5; p=0.008). stocktitan.net
- 3In a pooled post‑hoc analysis, 69.8% of participants achieved a ≥25% reduction in YGTSS tic severity within eight weeks. rttnews.com
- 4An interim open‑label extension with median exposure of 14.9 months showed a 45.6% mean reduction in tic severity through 18 months. indianpharmapost.com
- 5The FDA granted Priority Review and Orphan Drug designation for ecopipam in pediatric Tourette syndrome. stocktitan.net
- 6The Phase 2b D1AMOND trial enrolled 153 pediatric participants. rttnews.com
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.